1. Quantification of myocardial amyloid deposition in tafamidis-treated patients with transthyretin amyloid cardiomyopathy. (14th October 2021) Authors: Rettl, R; Wollenweber, T; Mann, C; Duca, F; Dachs, T.-M; Binder, C; Stojanovic, M; Camuz Ligios, L; Schrutka, L; Dalos, D; Charwat-Resl, S; Badr Eslam, R; Kastner, J; Hacker, M; Bonderman, D Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Two-dimensional speckle-tracking echocardiography in tafamidis-treated patients with transthyretin amyloid cardiomyopathy: a glimmer of hope for viable therapy monitoring?. (3rd October 2022) Authors: Rettl, R; Duca, F; Binder, C; Dachs, T; Cherouny, B; Camuz Ligios, L; Mann, C; Schrutka, L; Dalos, D; Charwat-Resl, S; Badr Eslam, R; Kastner, J; Bonderman, D Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗